<\/p>\n
Folitrax<\/strong> is an oral tablet from Ipca Laboratories containing methotrexate 7.5 mg<\/strong> — an antimetabolite (dihydrofolate reductase inhibitor) used for maintenance therapy of acute lymphoblastic leukaemia (ALL)<\/strong>, some lymphomas<\/strong>, severe rheumatoid arthritis<\/strong>, severe psoriasis<\/strong>, and other immune-mediated disease. Oncology maintenance dose: typically 15–30 mg\/m² per WEEK<\/strong> (NOT daily) — weekly dosing is the most critical safety point. Daily dosing of methotrexate by mistake is one of the most common preventable serious medication errors and can be fatal.<\/strong> Verplicht: folic acid 5 mg weekly<\/strong> on a different day; baseline + ongoing FBC, LFTs, U&E, CXR. Absolute contraindication in pregnancy and breastfeeding (potent teratogen).<\/p>\n<\/div>\n \ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n Folitrax is an oral tablet from Ipca Laboratories containing methotrexate 7.5 mg<\/strong>. Methotrexate is a folate antagonist (dihydrofolate reductase inhibitor) used at low doses for maintenance therapy of acute lymphoblastic leukaemia (ALL)<\/strong>, several lymphomas, certain solid tumours, and at similar low doses for severe rheumatoid arthritis, psoriasis, Crohn's disease and other immune-mediated conditions.<\/p>\n Standaard oncology maintenance<\/strong> dose: 15–30 mg\/m² per WEEK<\/strong> (typically 20–25 mg\/week for an adult). Standard rheumatology \/ dermatology<\/strong> dose: 7.5–25 mg per week.<\/p>\n Vaak voorkomend:<\/strong> nausea, mouth ulcers, fatigue, hair thinning, mild LFT rise, mild cytopenia.<\/p>\n Belangrijk:<\/strong><\/p>\nWhat Is Folitrax?<\/h2>\n
Toepassingen en Indicaties<\/h2>\n
\n
Dosage and How to Take — CRITICAL<\/h2>\n
\n
Bijwerkingen<\/h2>\n
\n
Warnings — CRITICAL<\/h2>\n
\n
Geneesmiddelinteracties<\/h2>\n